Volume 7.20 | May 24

Hematopoiesis News 7.20 May 24, 2016
Hematopoiesis News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HN on Twitter
A Humanized Bone Marrow Ossicle Xenotransplantation Model Enables Improved Engraftment of Healthy and Leukemic Human Hematopoietic Cells
Investigators showed that a xenotransplantation model bearing subcutaneous humanized ossicles with an accessible bone marrow microenvironment, formed by in situ differentiation of human bone marrow-derived mesenchymal stromal cells, enables the robust engraftment of healthy human hematopoietic stem and progenitor cells, as well as primary acute myeloid leukemia samples, at levels much greater than those in unmanipulated mice. [Nat Med] Abstract
Register Now for our Live Webinar- Anticipating Cytopenia: In Vitro Methods for Assessing Hematotoxicity
PUBLICATIONS (Ranked by impact factor of the journal)
Medial HOXA Genes Demarcate Hematopoietic Stem Cell Fate during Human Development
Using two-step differentiation, human embryonic stem cells differentiated in vitro into multipotent hematopoietic cells that had the CD34+CD38−/loCD90+CD45+GPI-80+ fetal liver hematopoietic stem/progenitor cells immunophenotype, but exhibited poor expansion potential and engraftment ability. [Nat Cell Biol] Abstract

Vascular Control of the Drosophila Hematopoietic Microenvironment by Slit/Robo Signaling
Researchers revealed that signals from the vascular system contribute to regulating the rate of blood cell differentiation via the regulation of posterior signaling center morphology. [Nat Commun] Full Article

Graphene Oxide Promotes Embryonic Stem Cell Differentiation to Hematopoietic Lineage
Investigators demonstrated that graphene oxide coated substrates significantly enhance the differentiation of mouse embryonic stem cells to both primitive and definitive hematopoietic cells. [Sci Rep] Full Article

Small Molecule Activation of NOTCH Signaling Inhibits Acute Myeloid Leukemia
Scientists report N-methylhemeanthidine chloride not only selectively inhibits acute myeloid leukemia (AML) cell proliferation in vitro but also hampers tumor development in a human AML xenograft model. [Sci Rep] Full Article

Pten Cell Autonomously Modulates the Hematopoietic Stem Cell Response to Inflammatory Cytokines
Investigators sought to clarify whether Pten cell autonomously or non-cell autonomously regulates hematopoietic stem cells (HSCs) mobilization. They also tested whether Pten deficiency affects the HSC response to granulocyte colony-stimulating factor and interferon-α since these cytokines induce HSC mobilization or proliferation, respectively. [Stem Cell Reports] Full Article | Graphical Abstract

Trib2 Suppresses Tumor Initiation in Notch-Driven T-ALL
The authors investigated the role of Trib2 in the initiation and maintenance of Notch-dependent T cell acute lymphoblastic leukemia (T-ALL). Trib2 had no effect on the growth and survival of murine T-ALL cell lines in vitro when expression was blocked by shRNAs. [PLoS One] Full Article


KPT-8602, a Second-Generation Inhibitor of XPO1-Mediated Nuclear Export, Is Well Tolerated and Highly Active against AML Blasts and Leukemia-Initiating Cells
Scientists report the anti-leukemic efficacy and tolerability of KPT-8602, a second-generation XPO1 inhibitor. KPT-8602 demonstrated substantially reduced brain penetration compared to selinexor, with resultant attenuation of the CNS-mediated side effects of anorexia and weight loss. [Leukemia] Full Article

Bendamustine, Etoposide and Dexamethasone to Mobilize Peripheral Blood Hematopoietic Stem Cells for Autologous Transplantation in Patients with Multiple Myeloma
The authors performed a prospective, nonrandomized Phase II study including 34 patients with multiple myeloma (MM) to evaluate bendamustine’s efficacy and safety as a stem cell mobilizing agent. [Bone Marrow Transplant] Abstract

SmartDish™ with STEMgrid™-6 for Accurate Counting of Hematopoietic CFU Assays
Lysine-Specific Histone Demethylases in Normal and Malignant Hematopoiesis
During the last ten years, mounting evidence implicates the family of lysine-specific histone demethylases as critical regulators of normal hematopoiesis, whereas their deregulation is found in a broad spectrum of hematopoietic malignancies. The authors review recent findings on the role of these enzymes in normal and malignant hematopoiesis to highlight how aberrant epigenetic regulation facilitates hematopoietic cell transformation through subversion of cell fate and lineage commitment programs. [Exp Hematol] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
SELLAS™ Life Sciences Announces Upcoming Presentation of Phase II Clinical Results for WT1 Cancer Vaccine at the 2016 ASCO Annual Meeting
SELLAS™ Life Sciences Group announced that results from a Phase II trial of the Company’s WT1 cancer vaccine, galinpepimut-S, in patients with acute myeloid leukemia will be presented. [Press release from SELLAS™ Life Sciences Group (PR Newswire Association LLC.) discussing research to be presented at the the Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago] Press Release

From our sponsor: Learn about applications of ALDHbr cells in regenerative medicine. Watch the video.
Gamida Cell Announces $4.4 Million Grant from the Israeli Government
Gamida Cell announced it has been awarded a grant of up to $4.4 million from the Israel Innovation Authority of the Israeli Ministry of Economy and Industry. The non-dilutive funding will support Gamida Cell’s ongoing research and development efforts including its Phase III registration study of NiCord® for hematological malignancies (blood cancers like leukemia and lymphoma), and its clinical trials of CordIn® for sickle cell disease and thalassemia and NK cells as a potential immune therapy for cancer. [Gamida Cell] Press Release

Janssen’s Single-Agent DARZALEX® (Daratumumab) Approved by European Commission for Treatment of Multiple Myeloma (MM)
Janssen-Cilag International NV announced that the European Commission has granted conditional approval to DARZALEX® for monotherapy of adult patients with relapsed and refractory MM, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. [Janssen-Cilag International NV] Press Release

Opdivo® (Nivolumab) Granted First Approval of a PD-1 Inhibitor in Hematology for the Treatment of Classical Hodgkin Lymphoma Patients Who Have Relapsed or Progressed After Auto-HSCT and Post-transplantation Brentuximab Vedotin by the FDA1
Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration (FDA) has approved Opdivo® for the treatment of patients with classical Hodgkin lymphoma who have relapsed or progressed after autologous hematopoietic stem cell transplantation (auto-HSCT) and post-transplantation brentuximab vedotin. [Bristol-Myers Squibb Company (Business Wire)] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW T-ALL Workshop
March 17-19, 2016
Leuven, Belgium

Visit our events page to see a complete list of events in the hematopoiesis community.
NEW Research Assistants and Associates – Leukemia and Stem Cell Biology (King’s College London)

Scientific Communications and Publishing Coordinator (STEMCELL Technologies Inc.)

Technical Sales Representative (STEMCELL Technologies Inc.)

Scientist – Hematology (STEMCELL Technologies Inc.)

Postdoctoral Research Associate – Myeloid Leukemia (Upstate Medical University)

Postdoctoral Fellow – Leukemia Lymphoma (Emory University)

Postdoctoral Scientist – Mouse Hematopoiesis (Lund University)

Postdoctoral Fellow – Hematopoietic Stem Cell Biology and Blood Disorders (Brigham & Women’s Hospital)

Research Technician – Hematopoietic Stem Cell Biology (Fred Hutchinson Cancer Research Center)

Postdoctoral Research Associate – Stem Cell Aging Biology (University of Southern California)

Postdoctoral Fellow – Hematopoietic Stem Cells (University of Pennsylvania)

Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital)

Assistant/Associate/Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us